Literature DB >> 9800796

Balance of proinflammatory and antiinflammatory cytokines at thoracic cancer operation.

D M Atwell1, K P Grichnik, M F Newman, J G Reves, W T McBride.   

Abstract

BACKGROUND: A homeostatic balance of proinflammatory and antiinflammatory cytokines is thought to be important for the maintenance of health. Cytokine baseline levels and response patterns to cardiac and nonmalignant abdominal operations have been investigated. The purpose of this study was to investigate the cytokine patterns at operation for thoracic cancer; the hypothesis tested was that cytokine baseline levels and response patterns would be unique for patients with malignant disease undergoing thoracic operation.
METHODS: Ten patients undergoing pulmonary tumor resections were studied. Blood samples were collected at six perioperative time points.
RESULTS: The cytokine response of these patients differed from patients undergoing cardiac operations: baseline tumor necrosis factor-alpha (39.1 pg/mL) and interleukin-10 (76.76 pg/mL) were elevated without significant changes. Interleukin-1 receptor antagonist became elevated postoperatively (871.6 pg/mL) compared with baseline (332.8 pg/mL) (p < 0.01). The level of tumor necrosis factor soluble receptor-2 was elevated at baseline (4,823.3 pg/mL) and remained elevated postoperatively (7,293.4 pg/mL) (p < 0.01).
CONCLUSIONS: Our hypothesis was supported; a separate pattern of proinflammatory and antiinflammatory cytokine levels and responses to thoracic operation was determined. This pattern may be indicative of tumor burden or detrimental to tumor surveillance; it merits further evaluation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9800796     DOI: 10.1016/s0003-4975(98)00592-x

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  7 in total

Review 1.  Present concepts on the inflammatory modulators with special reference to cytokines.

Authors:  A S J P A M Van Miert
Journal:  Vet Res Commun       Date:  2002-02       Impact factor: 2.459

Review 2.  Systemic inflammatory changes and their clinical implications following thoracic cancer surgery.

Authors:  Massimiliano Fornasiero; Georgios Geropoulos; Dimitrios Giannis; Joshua Enson; Julian Aquilina; Niraj Kumar; Kunal Bhakhri; Nikolaos Panagiotopoulos
Journal:  Indian J Thorac Cardiovasc Surg       Date:  2022-03-23

3.  Brain metabolomic profiles of lung cancer patients prior to treatment characterized by proton magnetic resonance spectroscopy.

Authors:  Helene Benveniste; Shaonan Zhang; Ruth A Reinsel; Haifang Li; Hedok Lee; Mario Rebecchi; William Moore; Christoffer Johansen; Douglas L Rothman; Thomas V Bilfinger
Journal:  Int J Clin Exp Med       Date:  2012-04-06

4.  Cytokine & chemokine response in the lungs, pleural fluid and serum in thoracic surgery using one-lung ventilation.

Authors:  Andreas Breunig; Franco Gambazzi; Beatrice Beck-Schimmer; Michael Tamm; Didier Lardinois; Daniel Oertli; Urs Zingg
Journal:  J Inflamm (Lond)       Date:  2011-11-11       Impact factor: 4.981

5.  Low Preoperative albumin-to-globulin ratio Predict Poor Survival and Negatively Correlated with Fibrinogen in Resectable Esophageal Squamous Cell Carcinoma.

Authors:  Xiao-Hui Li; Wen-Shen Gu; Xue-Ping Wang; Jian-Hua Lin; Xin Zheng; Lin Zhang; Ting Kang; Zhi-Xian Zhang; Wan-Li Liu
Journal:  J Cancer       Date:  2017-07-02       Impact factor: 4.207

6.  Elevated levels of anti inflammatory IL-10 and pro inflammatory IL-17 in malignant pleural effusions.

Authors:  Michail Klimatsidas; Kyriakos Anastasiadis; Christophoros Foroulis; Paschalis Tossios; Alexandros Bisiklis; Christos Papakonstantinou; Kyriakos Rammos
Journal:  J Cardiothorac Surg       Date:  2012-10-04       Impact factor: 1.637

7.  Novel and Stable Dual-Color IL-6 and IL-10 Reporters Derived from RAW 264.7 for Anti-Inflammation Screening of Natural Products.

Authors:  Papawee Saiki; Yasuhiro Kawano; Yoshihiro Nakajima; Leo J L D Van Griensven; Koyomi Miyazaki
Journal:  Int J Mol Sci       Date:  2019-09-18       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.